Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer

Second‐line treatment with immune checkpoint inhibition in patients with metastatic urothelial cancer (mUC) has a low success rate (~ 20%). Circulating tumour‐derived DNA (ctDNA) levels may guide patient stratification, provided that an affordable and robust assay is available. Here, we investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendelaar, Pauline A. J., Robbrecht, Debbie G. J., Rijnders, Maud, de Wit, Ronald, de Weerd, Vanja, Deger, Teoman, Westgeest, Hans M., Aarts, Maureen J. B., Voortman, Jens, Martens, John W. M., van der Veldt, Astrid A. M., Nakauma‐González, José Alberto, Wilting, Saskia M., Lolkema, Martijn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120908/
https://www.ncbi.nlm.nih.gov/pubmed/35181986
http://dx.doi.org/10.1002/1878-0261.13196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120908/
https://www.ncbi.nlm.nih.gov/pubmed/35181986
http://dx.doi.org/10.1002/1878-0261.13196

Ejemplares similares